Bukwang Pharm Signs Dexid Licensing and Exclusive Supply Deal in Saudi Arabia
Bukwang Pharm signed a technology-export and exclusive supply agreement for Dexid tablets with Saudi pharmaceutical company NASAQ on November 4, 2026.
Related stories
South Korean Shares Fall 1.38% as US Election Caution Weighs
The KOSPI fell 77.71 points, or 1.38%, to 5,571.08 at 0154 GMT after erasing early gains, as investors turned cautious ahead of US midterm election results.
M impact | EQUITY | Nov 04, 2026, 02:24 AM UTC
Angel One Orders Rise 4.2% Year Over Year in October
Angel One reported 139.31 million orders in October 2026, up 4.2% year over year.
M impact | EQUITY | Nov 04, 2026, 02:17 AM UTC
Angel One Client Base Rises 17.4% Year Over Year
Angel One reported 40.60 million clients in October 2026, up 17.4% year over year.
M impact | EQUITY | Nov 04, 2026, 02:16 AM UTC
Wingtech shares plunge 7.2% in early trading
China-based Wingtech Technology shares fell as much as 7.2% early Wednesday. Nexperia has filed a lawsuit against Wingtech’s founder.
M impact | EQUITY | Nov 04, 2026, 02:12 AM UTC
Nasdaq E-minis extend losses, down 1.6%
M impact | EQUITY | Nov 04, 2026, 02:12 AM UTC
AMD chip deals with OpenAI and Meta trigger a substantial quarterly charge
AMD's contracts with OpenAI and Meta involving chips are resulting in a quarterly charge.
L impact | EQUITY | Nov 04, 2026, 02:11 AM UTC